Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Prostate Cancer|Castration-resistant Prostate Cancer|Drug
Interventions: DRUG: Abiraterone Acetate|DRUG: Docetaxel
Sponsor: West China Hospital